Hui-Peng Lee

Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)

2021 | Lékařská fakulta v Hradci Králové

Publikace